Literature DB >> 16712612

Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients.

Avram Z Traum1, Nancy M Rodig, Monika E Pilichowska, Michael J G Somers.   

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a complication of transplantation resulting from impaired immune surveillance because of pharmacologic immunosuppression. We present two cases of central nervous system (CNS) PTLD in children on calcineurin-inhibitor free immunosuppression with dramatically different presentations and outcomes. One patient had brain and spinal cord lymphoma with a rapid and fatal course. The other patient had brain and ocular PTLD that responded to multimodal therapy with reduction of immunosuppression, high-dose steroids, and rituximab given in a dose-escalation protocol. This protocol may have enhanced the penetration of rituximab into the CNS. We review the literature on CNS and ocular PTLD and elaborate on the treatments available for both diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16712612     DOI: 10.1111/j.1399-3046.2006.00497.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  10 in total

1.  High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.

Authors:  A Patrick; A Wee; A Hedderman; D Wilson; J Weiss; M Govani
Journal:  J Neurooncol       Date:  2010-09-26       Impact factor: 4.130

Review 2.  Conservative management of post-transplant central nervous system lymphoma.

Authors:  Shahul H Valavoor; Zubair Ashraf; Rawan Narwal; Shobha Ratnam
Journal:  Int Urol Nephrol       Date:  2012-04-03       Impact factor: 2.370

3.  Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy.

Authors:  Valerie Said-Conti; Persis J Amrolia; Mark N Gaze; Sara Stoneham; Neil Sebire; Rukshana Shroff; Stephen D Marks
Journal:  Pediatr Nephrol       Date:  2013-06-07       Impact factor: 3.714

4.  Epstein-Barr virus induced post-transplant lymphoproliferative disorder presenting with unilateral retinal involvement.

Authors:  Mainguy Adam; Philippakis Elise; Aurélien Sutra Del Galy; Stanescu-Segall Dinu; Tadayoni Ramin; Bodaghi Bahram; Bonnin Sophie; Touhami Sara
Journal:  Am J Ophthalmol Case Rep       Date:  2021-08-02

5.  Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.

Authors:  Robert Cavaliere; Gina Petroni; Maria B Lopes; David Schiff
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

6.  Post-transplant lymphoproliferative disorder of the cauda equina in a kidney transplant recipient.

Authors:  Yuichiro Nishiyama; Akio Iwanami; Shuji Mikami; Soya Kawabata; Osahiko Tsuji; Narihito Nagoshi; Eijiro Okada; Nobuyuki Fujita; Mitsuru Yagi; Ken Ishii; Morio Matsumoto; Masaya Nakamura; Kota Watanabe
Journal:  Spinal Cord Ser Cases       Date:  2018-11-06

7.  Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients.

Authors:  Parag Mahale; Meredith S Shiels; Charles F Lynch; Eric A Engels
Journal:  Am J Transplant       Date:  2017-09-02       Impact factor: 9.369

8.  Epstein-Barr virus-associated posttransplant lymphoproliferative disorder involving the central nervous system following autologous hematopoietic stem cell transplantation for neuroblastoma.

Authors:  Hitoshi Sano; Masanobu Fujimoto; Keisuke Okuno; Jun-Ichi Ueyama; Shuichi Takano; Kazuhiko Hayashi; Susumu Kanzaki
Journal:  Springerplus       Date:  2014-10-06

9.  A Rare Presentation of Isolated CNS Posttransplantation Lymphoproliferative Disorder.

Authors:  Jaime Morris; Casey Smith; Andrew Streicher; Allison Magnuson; Susan Newman; Robert Bertoli
Journal:  Case Rep Oncol Med       Date:  2017-01-02

10.  Treatment of recurrent posttransplant lymphoproliferative disorder of the central nervous system with high-dose methotrexate.

Authors:  Clare J Twist; Ricardo O Castillo
Journal:  Case Rep Transplant       Date:  2013-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.